Implications Of Anemia Research Articles

A Cross-Sectional Study of Anaemia among Pregnant Women Visiting ANC Clinic in a Tertiary Care Centre

Background- Anaemia is one of the common health issues that pregnant women and children in developing countries face. Anaemia in pregnancy is related to poor fetal and maternal outcomes contributing to significant morbidity and mortality. Anaemia is a treatable and preventable condition. Aim - to determine the prevalence of anaemia among pregnant women visiting the ANC clinic in a tertiary care centre. Materials and methods- Total 100 pregnant women visiting the ANC clinic in a tertiary care centre were included in the study during the period of 5 months (December 2023 to April 2024) at VVP rural hospital, Loni. The World Health Organization's diagnostic criteria for anaemia was applied for determining hemoglobin levels. Demographic details and hemoglobin levels were collected. Data collected was analyzed using Microsoft Excel 2013 and pspp version 1.0.1. Results- Out of total 100 participants, 51 were anaemic. Out of them, 30 (58.8%) women had mild anaemia, 19 (37.3%) women had moderate anaemia and 2 (3.9%) women had severe anaemia. Mean age of women with Anaemia was 23.3 years as opposed to mean age of women without anaemia which was 26.7 years. Out of 51 cases, 10 (19.6%) women were primigravida, 32 (62.7%) women had birth spacing of less than 2 years, 9 (17.7%) women had birth spacing of 2 years or more. Conclusion- Prevalence of anaemia in our study was comparable to NFHS-5 data. There is need of antenatal and pre-conceptional health awareness about implications of anaemia, preventive measures and spacing between births which will reduce prevalence of anaemia, thus maternal and fetal morbidity and mortality.

Exploring Thyroid Dysfunction During Pregnancy: Implications for Anemia and Timing of Birth

Exploring Thyroid Dysfunction During Pregnancy: Implications for Anemia and Timing of Birth

Implications of anemia in patients undergoing PCI with Impella-support: insights from the PROTECT III study.

Anemia is prevalent among patients with cardiovascular disease and is associated with adverse outcomes. However, data regarding the impact of anemia in high-risk percutaneous coronary intervention (HRPCI) are limited. This study aimed to evaluate the impact of anemia in patients undergoing Impella-supported HRPCI in the PROTECT III study. Patients undergoing Impella-supported HRPCI in the multicenter PROTECT III study were assessed for anemia based on baseline hemoglobin levels according to World Health Organization criteria. Patients were stratified into three groups, namely, no anemia, mild anemia, and moderate or severe anemia. Major adverse cardiovascular and cerebrovascular events (MACCE: all-cause death, myocardial infarction, stroke/transient ischemic attack, and repeat revascularization) at 30 and 90 days, and major bleeding events were compared across groups. Of 1,071 patients with baseline hemoglobin data, 37.9% had no anemia, 43.4% had mild anemia, and 18.7% had moderate or severe anemia. Anemic patients were older and more likely to have comorbidities. Anemia was associated with higher MACCE rates at 30 days (moderate to severe, 12.3%; mild, 9.8%; no anemia, 5.4%; p = 0.02) and at 90 days (moderate to severe, 18.7%; mild, 14.6%; none, 8.3%; p = 0.004). These differences persisted after adjustment for potential confounders at 30 and 90 days, and sensitivity analysis excluding dialysis showed similar results. Major bleeding at 30 days was also higher in anemic patients (5.5% vs. 1.2%, p = 0.002). Baseline anemia in Impella-supported HRPCI is common and independently associated with MACCE and major bleeding, emphasizing its significance as a prognostic factor. Specific management strategies to reduce anemia-associated MACCE risk after HRPCI should be examined. Clinical Trial Information Trial Name: The Global cVAD Study (cVAD)ClinicalTrial.gov Identifier: NCT04136392URL: https://clinicaltrials.gov/ct2/show/NCT04136392?term=cvad&draw=2&rank=2.

Tackling the Immediate Implications of Anaemia in Women and Children

Anaemia persists as a significant global health issue, especially impacting women and children. Immediate consequences include fatigue, weakness, and impaired cognitive function, with pregnant women and young children facing elevated risks. Addressing anaemia requires widespread iron supplementation, nutritional education, and improved access to fortified foods. Resolving root causes like inadequate healthcare infrastructure and poverty is crucial. Collaborative efforts involving governments, NGOs, and the private sector are essential. Early detection, prompt treatment, and enduring preventive measures are vital. Community engagement and awareness campaigns are necessary for informed health decisions. By integrating these approaches, we can effectively tackle anaemia's immediate ramifications, aiming for a healthier future for vulnerable populations worldwide

Implications of anaemia and response to anaemia treatment on outcomes in patients with cirrhosis

Anaemia is frequently observed in patients with cirrhosis and was identified as a predictor of adverse outcomes, such as increased mortality and occurrence of acute-on-chronic liver failure. To date, the possible effects of iron supplementation on these adverse outcomes are not well described. We therefore aimed to assess the role of iron supplementation in patients with cirrhosis and its capability to improve prognosis. Laboratory diagnostics were performed in consecutive outpatients with cirrhosis admitted between July 2018 and December 2019 to the University Hospital Essen. Associations with transplant-free survival were assessed in regression models. A total of 317 outpatients with cirrhosis were included, of whom 61 received a liver transplant (n= 19) or died (n= 42). In multivariate Cox regression analysis, male sex (hazard ratio [HR]= 3.33, 95% CI [1.59, 6.99], p= 0.001), model for end-stage liver disease score (HR= 1.19, 95% CI [1.11, 1.27], p <0.001) and the increase of haemoglobin levels within 6 months (ΔHb6) (HR= 0.72, 95% CI [0.63, 0.83], p <0.001) were associated with transplant-free survival. Regarding the prediction of haemoglobin increase, intake of rifaximin (beta= 0.50, SD beta= 0.19, p= 0.007) and iron supplementation (beta= 0.79, SD beta= 0.26, p= 0.003) were significant predictors in multivariate analysis. An increase of haemoglobin levels is associated with improvement of transplant-free survival in patients with cirrhosis. Because the prediction of haemoglobin increase significantly depends on rifaximin and iron supplementation, application of these two medications can have an important impact on the outcome of these patients. Anaemia is very common in patients with cirrhosis and is known to be a predictor of negative outcomes, but little is known about the effect of iron substitution in these individuals. In our cohort, increase of haemoglobin levels improved transplant-free survival of patients with cirrhosis. The increase of haemoglobin levels was mainly induced by iron supplementation and was even stronger in the case of concomitant use of iron and rifaximin. UME-ID-10042.

Effects of anemia on the survival of patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

ABSTRACT Objectives Anemia is often seen in chronic obstructive pulmonary disease (COPD) patients. However, the implications of anemia on the outcomes of patients with COPD is not clearly known. Therefore, we conducted a systematic review and meta-analysis to evaluate the effects of anemia on the morbidity and mortality of patients with COPD. Methods We followed PRISMA guidelines to perform a systematic identification of relevant publications in the literature on four academic databases: MEDLINE, Scopus, EMBASE, and CENTRAL. Results Out of 1845 records, we included data from 15 articles including 420 970 participants in this review. Our systematic review presents a 2b level of evidence suggesting a higher duration of hospital stay, Charlson comorbidity index score, and mortality rate for patients with COPD and anemia than for patients with COPD without anemia. The meta-analysis revealed a moderate effect increase in the mean duration of hospital stay (Hedge’s g, 0.55), Charlson comorbidity index (0.68), and mortality rate (0.49) in patients with COPD and anemia as compared to those in patients with COPD without anemia. Conclusion The current systematic review and meta-analysis provide evidence regarding the detrimental consequences of anemia on the morbidity and mortality of patients with COPD.

Physiopathology and clinical implications of anemia in HIV adult patients

Physiopathology and clinical implications of anemia in HIV adult patients

CHARACTERISTIC FEATURES OF ANEMIC SYNDROME IN ONCOLOGICAL PATIENTS

Anemia is a common complication of oncological diseases that has a strong negative influence not only on the quality of life, but also on the effectiveness of specific treatment and survival rate. In the present review, current data on the pathogenesis and clinical implications of anemia in patients with malignancies are summarized. General principles underlying management of this group of patients are outlined on the basis of the results of recent clinical trials and guidelines. The safety issues related to administration of erythropoiesis-stimulating agents and vitamin B12 are discussed.

Study of the significance of iron deficiency indexes and erythrocyte parameters in anemic pregnant women and their newborns.

This study aimed to analyze the iron deficiency index and erythrocyte parameters in anemic pregnant women and their newborns, and explore their implications for anemia during pregnancy. Pregnant women (70) in the third trimester with hemoglobin (Hb) <100 g/L who registered and delivered from June 2012-2013 were randomly selected as the observation group, 70 pregnant women at similar gestational ages with Hb >110 g/L were selected as the control group, and 70 newborns delivered by women in each group were included in corresponding offspring observation and control groups, respectively. Periodic physical examinations were conducted on the infants, and blood samples were drawn from the women and infants at birth, 42 days, 4 months, and 6 months old for detection of Hb and soluble transferrin receptor (sTfR) levels. Pregnant women and their 6-month-old infants in the observation group had significantly different Hb and sTfR levels compared to controls (P < 0.01). There were no significant differences in Hb and sTfR levels of infants at birth, 42 days, and 4 months old (P > 0.05). The detection rate of iron deficiency anemia (IDA) was significant, at 61.43% among 6-month-old infants in the observation group and 22.86% among controls (P < 0.01). There were no significant differences in the detection rate of IDA among infants at birth, 42 days, and 4 months old between observation and control groups (P > 0.05). Therefore, anemia during pregnancy is a major contributing factor of IDA and subclinical iron deficiency among 6-month-old infants.

Socio-Demographic Correlates of Anaemia among Adolescents in Urban Slum

Background : Adolescence - a period of transition between childhood and adulthood is a significant period of human growth and maturation. Adolescents represent about a fifth of India's population. Iron needs are highest in males during peak pubertal development because of a greater increase in blood volume, muscle mass and myoglobin. Many studies in recent times have highlighted the high prevalence of anaemia among adolescent girls in India, however, there is limited published literature on prevalence of anaemia among adolescent boys. Aims : 1. To find out the prevalence of anaemia among adolescent (10-19 years) boys and girls in the urban slum of Meerut. 2. To study socio-demographic co-relates of anaemia. Material and Method : A Community based cross sectional study was conducted in urban slum, Multan nagar, catchment area of Urban Health and Training Center, Department of Community Medicine, Subharti Medical College, Meerut. A total of 406 (216 females and 190 males) adolescents (10 -19 years of age) were included in this study. Haemoglobin estimation was done using Direct Cyanmethaemoglobin method. Statistical analysis were done using Microsoft excel 2007 and Epi info version 3.5.3. Results : The prevalence of anaemia among adolescent males and females was found to be 31.6% and 52.8% respectively. Statistical significant association (p< 0.05) of anaemia among boys were found with type of family, socio-economic status, educational status&academic performance. Among females, the statistical significant socio-demographic factors were socio-economic&educational status. Conclusions : A high prevalence of anaemia was found among adolescent males and females. Considering the possible implications of anaemia on adolescent growth and development, the nutritional status of adolescents should not be overlooked and suggests the need for routine iron supplementation even among adolescent boys.

AS-219 Prognostic Implication of Anemia on Clinical Outcomes After Percutaneous Coronary Intervention with Drug-Eluting Stent

AS-219 Prognostic Implication of Anemia on Clinical Outcomes After Percutaneous Coronary Intervention with Drug-Eluting Stent

Effect of Nutritional Counseling and Alfalfa Supplementation on Exercise Performance and Nutritional Anemia of Overweight and Obese Adult Females

Overweight and obesity are affecting the quality of life worldwide. Diet modification and exercise form an essential part of successful management strategy. However, low calorie diets might induce nutritional imbalances resulting in health problems such as anemia which impairs the body’s ability to exercise thus making weight loss difficult. Research on the implication of anemia and its management on exercise performance is scarce, especially in India. Thus, the present study aimed to assess the effect of nutritional counseling and iron and folic acid rich alfalfa powder supplementation on exercise performance and anemia of adult overweight and obese females undergoing weight loss program. Seventeen overweight and obese anemic females (age 36.3 ± 10.75 years) were enrolled from gyms using purposive sampling technique purely based on their willingness to participate and were assessed for indices of obesity (WHR, MUAC, %BF), exercise performance (Cooper’s test, sit-ups test) and anemia status at the start of the study, after 8 weeks of nutritional counseling, and then after supplementation with alfalfa powder (5g) for 4 weeks. A significant reduction in the anthropometric indices of obesity (p£.01), improvement in the cardiovascular fitness (p£.01) and few markers of anemia status like RDW, TIBC, serum iron and percent RBC saturation were noticed after 8 weeks of nutritional counseling (PNC). RDW and TIBC improved on supplementation with alfalfa. Thus, diet modification along with supplementation with micronutrient rich foods might control anemia and improve exercise ability of overweight and obese females, thereby help them achieve normal body weight.

Myocardial and Systemic Iron Depletion in Heart Failure: Implications for Anemia Accompanying Heart Failure

Myocardial and Systemic Iron Depletion in Heart Failure: Implications for Anemia Accompanying Heart Failure

Diagnóstico y tratamiento de la anemia en pacientes con enfermedad renal crónica en todos sus estadios. Consenso del Anemia Working Group Latin America (AWGLA)

The present consensus document of the Anemia Working Group Latin America (AWGLA) considers all stages of chronic kidney disease in adults older than 18 years, from the predialysis phase until the dialysis phase, both peritoneal dialysis and hemodialysis, and renal transplantation. Many of the recommendations are common to all phases while others may be applicable in only one particular phase, as indicated in the document when appropriate. The guideline is divided into the following parts: the importance and implications of anemia in chronic kidney disease, diagnosis of anemia, study of anemia of renal origin, the hemoglobin range to be achieved, the frequency of monitoring of hematic parameters, diagnosis of iron deficiency, treatment of iron deficiency, use of erythropoiesis-stimulating agents, use of other adjuvant agents, transfusional therapy, and anemia in renal transplantation.

Prevalence and Clinical Implications of Anemia in Congestive Heart Failure Patients Followed at a Specialized

The objective of this study was to assess the prevalence of anemia and to investigate its association with comorbidities and its impact on clinical outcomes in patients with heart failure. The association of predefined anemia, as well as the correlation of serum hemoglobin level as a continuous variable, with outcomes of emergency department visits, hospitalization, and mortality was investigated. There were fewer anemic patients in New York Heart Association classes I and II than in classes III and IV. Anemia was associated with higher rates of emergency department visits, hospital admissions, and all-cause mortality. Multivariable analysis showed that anemia is independently associated with mortality. When hemoglobin level was considered as a continuous variable, the authors noted that the mortality risk correlated with hemoglobin level disappears when hemoglobin level exceeds 140 g/L. The authors conclude that anemia has strong impacts on functional class and other clinical outcomes in patients with heart failure.

Perioperative anemia as prognostic factor in patients undergoing resection for non-small cell lung cancer

7179 Background: In order to explore the clinical implications of anemia as indicator of prognosis, we undertook a study to assess the correlation of preoperative anemia and perioperative blood tra...

Implications of anemia in human immunodeficiency virus, cancer, and hepatitis C virus.

Anemia is a multifactorial problem in patients with human immunodeficiency virus (HIV) infection, cancer, and hepatitis C virus (HCV) infection. New insights regarding anemia symptoms and quality of life (QOL) have prompted reassessment of traditional triggers for anemia treatment to increase hemoglobin (Hb) and improve QOL. In HIV-positive patients, anemia is independently associated with disease progression and survival. Many HIV-positive patients receiving highly active antiretroviral therapy (HAART) still develop mild to moderate anemia and associated QOL impairment. Epoetin alfa effectively increases Hb and improves QOL in these patients. Many HIV-positive patients are coinfected with HCV. Standard HCV therapy (interferon alfa/ribavirin) can cause anemia that may result in treatment alterations and compromised virologic outcome. Epoetin alfa therapy in anemic HCV patients increases Hb levels and may provide other benefits. Neuroprotective effects of epoetin alfa in preclinical models of central nervous system disorders have recently been demonstrated, implying a new therapeutic role for this cytokine.

Implications of Anemia: Focus on Managing Patients Infected with HIV and HCV

Implications of Anemia: Focus on Managing Patients Infected with HIV and HCV

The Implications of Anemia in Multiple Myeloma

Multiple myeloma (MM) is commonly associated with anemia. Several causes have been implicated, but anemia of chronic disease with inadequate erythropoietin (EPO) production related to the inflammatory cytokines appears to be of utmost importance. Interleukin-1 and tumor necrosis factor are capable of suppressing erythropoiesis. Anemia has broad implications. First, the low hemoglobin and hematocrit are associated with poor quality of life and performance and affect daily activity. Second, anemia has an impact on the cardiovascular system. Considering that most MM patients are elderly, this may be even more important. Anemia has been shown to induce or aggravate hypoxia and ischemic complications. Third, anemia has been shown to be a poor prognostic factor in MM. Traditionally, patients with symptomatic anemia were treated with red blood cell transfusions as needed. The introduction of epoetin alfa and epoetin beta into clinical practice opened new avenues to these patients. The administration of epoetins to patients with MM and anemia have been shown to be very useful. Several studies in more than 1000 patients have demonstrated a high response rate (range, 25%-85%; mean, 60%). This response is characterized by a significant increase of hemoglobin, hematocrit, and the number of red blood cells together with a reduction in the blood transfusion requirements. This is also associated with an improved quality of life. Although there is no complete agreement about the role of pretreatment serum EPO levels, many investigators believe that relatively low levels may help in predicting response, thereby limiting the number of potential candidates to receive this expensive therapy. The epoetins are safe and well tolerated with minimal toxicity; however, some concern has been recently raised regarding several dozen patients who developed pure red cell aplasia while on epoetin therapy. However, this adverse effect appears to be extremely rare. Recent data suggest that EPO has additional biologic effects, such as longer-than-expected survival in patients with MM. This observation is further supported by animal studies, demonstrating an antimyeloma effect of EPO in mice models. This effect has been shown to be immune mediated. If these exciting data are confirmed in future clinical trials, this may have significant implications on the treatment of MM.